MEDICINE DETAILS
Opzelura
Active ingredient: Ruxolitinib
Official EU and U.S. records identify Opzelura as a topical cream containing ruxolitinib. The way its strength is written and the pack sizes shown differ between jurisdictions, so match the complete cream strength and tube size.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Opzelura used for?
Opzelura (ruxolitinib) is a Janus kinase (JAK) inhibitor.
It's indicated for the short-term and non-continuous treatment of:
- Mild to moderate eczema (atopic dermatitis) in non-immunocompromised (without weakened immune systems) people over the age of 12. Opzelura (ruxolitinib) is intended for patients who don’t qualify for or benefit from topical prescription therapies.
- Opzelura is also approved for treating non-segmental vitiligo in patients aged 12 and up.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Opzelura identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
OFFICIAL RECORD SUMMARY
Product details checked against regulatory sources
Official EU and U.S. records identify Opzelura as a topical cream containing ruxolitinib. The way its strength is written and the pack sizes shown differ between jurisdictions, so match the complete cream strength and tube size.
- ✓EU record: 15 mg/g cream in a 100 g tube
- ✓U.S. record: 1.5% cream in 60 g and 100 g tubes
Presentations can differ by jurisdiction and authorisation. This list is not a use or dosing recommendation.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
15 mg/g cream · 100 g Catalogue organisation: Incyte Biosciences Distribution B.V.
OFFICIAL SOURCES
Check the Opzelura record at an official source.
Search for “Opzelura” or “Ruxolitinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗ PRODUCT-SPECIFIC OFFICIAL RECORD EMA — Opzelura EPAREuropean public assessment information for Opzelura.
↗ PRODUCT-SPECIFIC OFFICIAL RECORD FDA — Opzelura prescribing informationFDA-approved U.S. prescribing information and presentation details.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Opzelura.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Opzelura
01What is Opzelura?＋
This directory record associates the brand name Opzelura with the active ingredient Ruxolitinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Opzelura strengths and packs are recorded?＋
The catalogue currently shows: 15 mg/g cream · 100 g. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Opzelura?＋
Catalogue records currently name: Incyte Biosciences Distribution B.V.. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Opzelura?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Opzelura, payment request, stock guarantee or binding offer.
06Can I buy Opzelura from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.